Loading...
Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
BACKGROUND: Overexpression of the ERBB2 kinase is observed in about one-third of breast cancer patients and the dual ERBB1/ERBB2 kinase inhibitor lapatinib was recently approved for the treatment of advanced ERBB2-positive breast cancer. Mutations in the ERBB2 receptor have recently been reported in...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Public Library of Science
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3203921/ https://ncbi.nlm.nih.gov/pubmed/22046346 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0026760 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|